The analysis of the assortment and the availability of peristalsis stimulants at the pharmaceutical market of Ukraine

Authors

DOI:

https://doi.org/10.24959/cphj.19.1492

Keywords:

peristalsis stimulants, assortment of drugs, pharmaceutical market, the rate of solvency adequacy

Abstract

Peristalsis stimulants are one of the main drugs used to treat motility disorders of the upper gastrointestinal tract.
Aim. To analyze the assortment of peristalsis stimulants at the pharmaceutical market of Ukraine and the dynamics of their economic availability for consumers in 2014-2018.
Materials and methods. The assortment of peristalsis stimulants in Ukraine was determined by using the data of the system “Pharmexplorer” of the company “Morion”, and the economic availability was assessed by using the rate of solvency adequacy.
Results. Peristalsis stimulants were presented in Ukraine by 4 international non-proprietary names in 2014-2018. The number of their trade names (TN) varied from year to year and ranged from 32 to 35 TN, almost in equal proportions of drugs of domestic and foreign manufacturers. The range of prices for packaging of drugs of this group was wide. Domperidone and mozapride drugs had a high availability for the population among peristalsis stimulants during the
study period. The availability of metoclopramide decreased over the years due to an increase in the amount of its TN with a high price for packaging in Ukraine. The drugs of itoprid hydrochloride had the least availability for the population of Ukraine in 2014-2018 because of the long course of treatment and the high cost of packaging.
Conclusions. Peristalsis stimulants were presented in Ukraine in 2014-2018 in the assortment that was sufficient to select drugs for patients with a different solvency. Most drugs of this group had a high and medium availability for the course of treatment for the average inhabitant of Ukraine within 2014-2018.

Author Biographies

O. O. Gerasymova, National University of Pharmacy

Сandidate of Pharmacy (Ph.D.), associate professor of the Department of Pharmacoeconomics

V. V. Krykun, National University of Pharmacy

student of the specialty «Clinical Pharmacy»

References

Mynushkyn, O. N., Maslovskyi, L. V., Anykyna, N. Yu. (2016). Medytsynskyi sovet,14, 36–176.

Trukhan, D. Y. (2017). Medytsynskyi sovet, 5, 108–115.

Benca, T. M. (2010). Krims'kij terapevtichnij zhurnal, 2, 171–176.

Pahomova, I. G. (2013). Medytsynskyi sovet, 6, 33–38.

Tarasova, L. V., Truhan, D. I. (2015). Acta medica Eurasica, 4, 29–40.

Palii, I. H. (2013). Praktykuiuchyi likar, 3, 25–30.

Kljaritskaja, I. L., Moshko, Ju. A. (2011). Krims'kij terapevtichnij zhurnal, 2, 45–49.

Kareva, E. N., Serebrova, S. Iu. (2017). Eksperimentalnaia i klinicheskaia gastroenterologiia, 143(7), 167–183.

Yakovlieva, L. V., Perederii, A. V. (2015). Upravlìnnâ, ekonomìka ta zabezpečennâ âkostì v farmacìï, 4(42), 87–94.

Kotvitska, A. A., & Kostiuk, V. H. (2016). Farmatsevtychnyi chasopys, 2, 48–53.

Mnushko, Z. M., Akhmed Karam, Sofronova, I. V. (2010). Ukrainskyi zhurnal klinichnoi ta laboratornoi medytsyny, 5 (2), 53–57.

Nemchenko, A. S., & Fursa, L. I. (2016). The marketing research of anticancer drugs for the treatment of lung cancer. Socìalʹna farmacìâ v ohoronì zdorov’â, 2(2), 59–67.https://doi.org/10.24959/sphhcj.16.37

Systema doslidzhennia rynku likarskykh zasobiv «Pharmexplorer» kompanii «Morion». (n.d.). Available at: https://www.pharmstandart.com.ua

Dovgun, S. S. (2012). Sovremennye problemy nauki i obrazovanija,2, 33–39.

Kompendium. Likarski preparaty. (n.d.). Available at: https://compendium.com.ua/uk/

Downloads

Published

2019-05-31

Issue

Vol. 23 No. 2 (2019)

Section

Pharmacoeconomics

License

Copyright (c) 2019 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).